CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FierceBiotech
Original article

{"a":[{"_":"Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx","$":{"href":"/biotech/latigo-laces-247m-ipo-fund-non-opioid-pain-drug-rival-vertexs-journavx","hreflang":"en"}}]}

IPO/OfferingJournavxPositive
AI Analysis

Summary

Latigo Biotherapeutics announced plans for a $247M IPO to fund development of its clinical-stage non-opioid pain management drug pipeline, positioning itself as a competitor to Vertex's Journavx.

Importance:6/10
Sentiment:
0.60
IPOnon-opioid painclinical-stagefundraising
Related Companies

Read the original article

Published by FierceBiotech on August 4, 2026 7:56 AM

Read Original